Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01121276 · ClinicalTrials.gov registry record · Phase 1
A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
NCT01121276 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 82 participants.
The verdict
NCT01121276, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
Study Summary
This trial is conducted in Europe and in the United States of America (USA). The aim of this trial is to investigate the absorption and effect in the body of NN1218 in subjects with type 1 and type 2 diabetes.
Interventions
- DRUG insulin aspart
- DRUG Faster-acting insulin aspart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01121276
The ClinicalTrials.gov registry entry for NCT01121276 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which insulin aspart is the first listed.
NCT01121276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01121276 about?
NCT01121276 is a clinical study titled "A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes". This trial is conducted in Europe and in the United States of America (USA). The aim of this trial is to investigate the absorption and effect in the body of NN1218 in subjects with type 1 and type 2 diabetes.
What is the current status of trial NCT01121276?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2010-04. Estimated completion is 2010-09.
What interventions are being tested in trial NCT01121276?
The interventions under investigation include: insulin aspart (DRUG), Faster-acting insulin aspart (DRUG).
Who is sponsoring clinical trial NCT01121276?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.